Introduction
Over 600 000 Americans and 750 000 Europeans currently suffer from end stage renal disease (ESRD); of these an estimated 100 000 patients in the USA and 90 000 in Europe require initiation of renal replacement therapy each year. 1, 2 Of the three types of vascular accesses employed for chronic haemodialysis, the autogenous, surgically created arteriovenous fistula (AVF) is the most favoured, whereas the tunnelled central venous catheter (CVC) is the least desired. [3] [4] [5] [6] AVFs are favoured because their use is associated with reduced risk for infections, lower morbidity and mortality, and fewer interventions to maintain patency. The creation of an AVF or arteriovenous graft (AVG) leads to a localized area of high flow shunting of blood from the arterial to venous circulation, and exposes the low pressure, high capacitance venous system to the high pressure, low capacitance arterial system. This decreases total systemic vascular resistance while simultaneously increasing venous return to the heart, thus increasing cardiac output. Creation of AVF is also a well-established method to create animal models of heart failure (HF), 7 resulting in ventricular remodelling and myocardial dysfunction that are coupled to the high flow state. Case reports and small, short-term observational studies have related AVF creation to cardiac remodelling, neurohormonal activation and the development of high output HF, [8] [9] [10] but there are no published data on the long-term cardiovascular structural and functional changes that accompany AVF creation in patients with ESRD, 11 forming the basis for this study.
Methods
This is a retrospective analysis including all consecutive patients undergoing AVF or AVG creation over a 15-year period from January 2000 to January 2014 at the Mayo Clinic in Rochester, MN. All patients included in the analysis were required to undergo echocardiography <3 months before and >6 months following dialysis access to allow for chronic, longitudinal assessment of cardiac structure and function. If multiple echocardiograms were performed following AVF/AVG surgery, the most recent was used. Exclusion criteria included patients with preexisting AVF or AVG, hyperthyroidism or other high-output state, endocarditis or sepsis at the time of echocardiogram, intracardiac shunting, significant valvular heart disease (>mild stenosis, >moderate regurgitation), pulmonary hypertension on vasodilators, constrictive pericarditis, primary cardiomyopathies, or heart transplant. Patients with failed AVFs/AVGs between Exams 1 and 2 were excluded. If AVF/AVG failure occurred after the Exam 2 echocardiogram, patients were censored at that time for outcomes. Patients experiencing interim myocardial infarction, revascularization or cardiac resynchronization that could independently affect cardiac structure or function, independent of the AVF/AVG, were also excluded. The study was approved by the Mayo Clinic institutional review board.
Clinical data
Coronary artery disease was defined by history of epicardial stenosis >50% on angiography, prior myocardial infarction, or any prior revascularization. Diabetes was defined by treatment with anti-diabetic medications. Hypertension was defined by BP > 140/90 mmHg or treatment with antihypertensive medications. Laboratory tests, including haemoglobin and haematocrit, were obtained on the day of echocardiography. Estimated plasma volume was determined by the following formula: (1 -haematocrit) Â [a þ (b Â weight in kg)] where a = 1530 in males and 864 in females, and b = 41 in males and 47.9 in females. 12 
Assessment of cardiac structure and function
Echocardiography was performed according to ASE guidelines and interpreted by Mayo staff cardiologists. 13, 14 Stroke volume was calculated as the product of the cross-sectional area of the left ventricular (LV) outflow tract and the time-velocity integral obtained during pulse wave Doppler. LV systolic function was assessed by ejection fraction (EF) and the velocity of longitudinal shortening during systole at the septal mitral annulus (s'). LV diastolic function was assessed by the velocity of early diastolic blood flow (E), septal diastolic annular tissue velocities (e') and the ratio of E/e'. Left atrial volume index was determined by the biplane method of disks. Right atrial (RA) pressure was estimated from the IVC diameter. Right ventricular (RV) systolic pressure (RVSP) was calculated as (4 Â peak tricuspid regurgitation velocity) þ estimated RA pressure.
RV structural and functional indices were measured in a blinded fashion by an experienced cardiologist (M. O.) in accordance with contemporary guidelines. 15 RV area was traced in the 4 chamber view at end-systole and end-diastole to quantify RV size and to calculate the RV fractional area change (FAC) as a quantitative index of RV systolic function. 15 In addition, RV dilation and dysfunction were reported based on qualitative visual estimation, graded ordinally as normal, mild, moderate or severe dilation or dysfunction, respectively. 15 This qualitative assessment by experienced sonographers incorporates multiple views and parameters of RV size and function and has been shown to be strongly prognostic with good correlation with quantitative measures in our laboratory. 16 
Outcome assessment
Prevalent and incident HF was defined using the Framingham criteria, with diagnoses adjudicated by a staff cardiologist. The echocardiogram following AVF (Exam 2) was compared with the echocardiogram preceding AVF creation (Exam 1) to define the following four primary outcome variables: (i) the interval development of LV dilation (defined by an increase in LV end diastolic dimension of > _4 mm), (ii) development of LV dysfunction (LVEF < 40%), (iii) development of worsening RV dysfunction (any increase in RV dysfunction grade), and (iv) worsening RV dilation (any increase in qualitative RV dilatation). Mortality was first assessed by clinical chart review and by cross referencing the Mayo Clinic registration database, the Rochester Epidemiology Project death database and the Social Security Death Index. Patients who were deemed alive on this screen were prospectively contacted, thus allowing 100% complete assessment of vital status.
AVF ligation
A separate cohort of 84 patients undergoing AVF ligation between the same dates was identified to assess the reversibility of cardiac changes due to the fistula. From this group, 35 patients with paired echocardiograms before and after complete AVF ligation were included.
Statistical analysis
Data are reported as mean and SD or median (25-75th interquartile range). Analysis of Variance, Chi square, McNemar's test or t test was used as appropriate to examine differences between groups. Differences in LV structure and function after AVF/AVG creation were evaluated by paired t test or Wilcoxon ranked sum test. To counteract the problem of multiple hypotheses testing, the Holm-Bonferroni correction was applied to the primary study endpoints of LV and RV size/function. 17 Logistic regression was used to identify predictors for the incident development of RV dilatation or dysfunction using prospectively-defined variables expected to increase risk for the latter events. Significant predictors on univariate logistic regression (P value < 0.05) in addition to a priori determined variables of clinical significance were entered into multivariable logistic regression models to determine their independent effects on the outcome of interest. Survival was assessed by the Kaplan-Meier method and adjustment was made for baseline differences by Cox regressional analysis in calculation of Hazard ratios. All patients who received AVF/AVG at Mayo continued to follow within the Mayo system for dialysis and were followed until death, or were censored at the time of ligation of AVF/AVG (as clinically indicated for HF or infection), or occurrence of myocardial infarction after the post AVF/AVG echo to exclude their effect on outcomes independent of the effect of the AVF on haemodynamics. All tests were two-sided, with a P-value < 0.05 considered significant. Analyses were performed using JMP 10.0.0 (SAS Institute, Cary, NC).
Results
Between 1 January 2000 and 2014, 2,236 patients underwent creation of AVF or AVG at Mayo Clinic for the initiation of haemodialysis. From this cohort, 137 patients had paired echocardiographic examinations before and after surgery comprising the study population. Baseline characteristics and ventricular function were similar comparing study subjects with a random sample (n = 200) of excluded patients (see Supplementary material online, Table S1 Patients were older-aged, obese, anemic, and displayed multiple comorbidities, in keeping with a typical ESRD population ( Table 1) . Over half of subjects had preexisting HF at the time of surgery. The majority of patients (88%) had an upper arm AV access created, and 91% of the patients had an AVF created compared with 9% who had an AVGplaced. Although there are no published data on haemodynamic differences between AVFs and AVGs, the term 'AVF/AVG' is used collectively in this study to refer to the dialysis access shunt, as a subset, albeit small (9%), involved an AVG rather than an AVF.
Changes in cardiac structure and function with AVF
Initiation of haemodialysis between Exams 1 and 2 was associated with an 8% reduction in body weight coupled to a 9% decrease in estimated plasma volume and 13% reduction in arterial blood pressure ( Figure 1 , Table 2 ). Heart rate increased by an average of 5 bpm (P = 0.003). Stroke volume decreased modestly while cardiac output did not change.
Decreases in fluid volume, body weight and arterial pressure from Exams 1 to 2 were associated reductions in LV size and mass ( Table 2) . Development of LV dilation and dysfunction was relatively uncommon with AVF/AVG, occurring in 17 and 15% of patients, respectively. In contrast, LA volume index increased by $10% from Exams 1 to 2 (P = 0.004, Table 2 ). This was coupled with an increase in the prevalence of atrial fibrillation from 24 to 39% (P < 0.001, Table 2 ). From Exams 1 to 2, there was a slight reduction in LV systolic function, evidenced by decreases in LV EF and s' velocity ( Table 2) . There was no change in LV diastolic function.
RV size increased and RV function worsened from Exams 1 to 2, reflected by increases in RV areas and decreases in FAC (Table 2, Figure 2 ). Worsening RV dilation and dysfunction were observed by qualitative interpretation in 37 and 34% of patients following AVF, respectively. The sample size of 137 with two-sided a = 0.05 provides 93% power to detect differences in the proportion of RV dilation observed and 99.8% power to detect the discordant proportions observed for worsening RV dysfunction. Observed differences in RV size and function following AVF/AVG remain significant after adjusting for multiple comparisons (P < 0.001 for each).
Predictors of RV dilation are shown in Table 3 . Although baseline clinical HF was associated with subsequent RV dilation on univariate analysis, after multivariable adjustment, only age tended to be associated with RV dilation (P = 0.09, Table 3 ). Baseline quantitative parameters of RV size and function did not predict subsequent adverse RV remodelling. There were no differences in the changes in haemodynamics, LV structure/function, or RV structure/function following AVG as compared with following AVF (all P > 0.1) (data not shown).
Outcomes
Between Exams 1 and 2, 28 of the 65 patients with no prior HF diagnosis at the time of AVF/AVG creation (43%) developed incident HF. Of patients developing incident HF, 75% had HF with preserved EF Figure 3) . Over a median follow up duration of 3.9 (IQR 2.4, 6.4) years, there were 103 deaths (75%). Baseline RV dilation did not predict subsequent mortality ( Figure 4A) . However, the development of worsening RV dilation following AVF/AVG creation was strongly associated with increased risk of death [HR 3.9, 95% CI (1.7-9.2), P = 0.001). This association with increased mortality persisted after multivariable adjustment for other predictors (Table 4, Figure 4B ).
To assess if improvement in ESRD management over time modified the effect of RV dilation on survival, we performed a sensitivity analysis stratified by dialysis access creation before or after 2007. Worsening RV dilation remained associated with increased mortality after AVF/AVG creation both after 2007 (median survival 4.5 
Effect of AVF ligation
To better understand the effects of AVF on cardiac structure and function, a separate cohort of 35 patients were identified who underwent AVF ligation with echocardiography performed preligation (median 114 days) and post-ligation (median 387 days) to examine longitudinal changes following removal of shunt physiology ( Table 1) . AVF ligation was associated with reductions in LVEDD (P = 0.03) and LVMI (P = 0.07), but there was no change in LV systolic or diastolic function. There were reductions in estimated RA pressure (P = 0.03) and RVSP (P = 0.03, Table 5 ). There was not reverse remodelling in the RV, but 84% of patients had stable or improving RV function and 81% of patients had stable or improving RV size after AVF ligation. AVF ligation was not associated with decreased mortality (data not shown).
Discussion
This is the first study to characterize chronic, longitudinal changes in cardiovascular structure and function in patients with ESRD after the surgical creation of an AVF/AVG for haemodialysis access. Following AVF, there were significant reductions in arterial blood pressure, body weight and estimated plasma volume, indicating decreased LV pressure load with control of hypervolemia from renal replacement therapy. These changes were associated with modest reductions in LV size and mass. LV systolic function decreased slightly following AVF/AVG whereas diastolic function remained unchanged. In contrast to reductions in LV size, AVF/AVG creation was associated with significant dilatation in the left atrium and RV, changes that were associated with the development of incident HF and increased risk of death. Ligation of AVF attenuated further RV remodelling, but did not correct biventricular dysfunction. These data provide new insight into the long-term changes in cardiovascular structure and function that develop following AVF/AVG creation in people with ESRD, suggesting that while improved fluid management reduces LV pressure load and remodelling, volume loading from peripheral surgicalinduced shunting may place major stresses on the right heart, resulting in adverse RV remodelling and dysfunction that are associated with increased risk of all-cause mortality and new-onset HF. Cardiovascular disease, and in particular HF, is the leading cause of death in patients on dialysis. 18 The mechanisms underlying the increased HF risk in ESRD are poorly understood but are believed to be related to the chronic adverse effects of systemic hypertension in conjunction with volume overload, the direct cardiomyopathic effects of the uremic milieu, increased aortic stiffness, metastatic vascular calcification, chronic inflammation, accelerated atherosclerosis, and adverse neurohumoral effects on the heart instigated by the failing kidney. 19 The current standard of care for patients initiating haemodialysis is based on the 'Fistula First' initiative which regards the AVF as the most favoured dialysis access followed by the AVG. Compared with the tunnelled CVC, the AVF is associated with lower rates of infections, hospitalizations and mortality; compared with the AVG, the AVF requires fewer interventions to maintain access patency and may exhibit longer functionality. [4] [5] [6] However, data from some studies from the USA and Europe suggest that mortality and HF prevalence may be increased in AVF patients when compared with patients receiving peritoneal dialysis. [20] [21] [22] Connecting an artery to a vein leads to 'wasted' blood flow because the fistula flow does not contribute to tissue perfusion. Cardiac output and ventricular work increase in the setting of decreased arterial resistance, while venous return to the heart increases substantially, augmenting volume load. 22 28 this is the first long-term, large scale study to show the adverse chronic cardiac effects in patients with ESRD in whom an AVF or AVG is created, and relate these changes to adverse clinical outcomes in a broad cohort of patients undergoing AVF/AVG creation to initiate dialysis.
Changes in left heart structure and function following AVF/AVG
The current data show that chronically ($2-year interval), creation of an AVF/AVG with initiation of dialysis is associated with improved fluid and blood pressure control that is then coupled with modest LV reverse remodelling. This result contrasts with data from smaller, short-term studies demonstrating LV dilation after fistula creation 9, 29 The reason for the discrepant results is unclear, but we speculate that over longer intervals, beneficial reductions in pressure overload from renal replacement therapy outweigh deleterious effects of volume overload introduced by the high flow AVF, at least in the left ventricle. The discrepant effects between these studies may also reflect the beneficial effects arising from long-term haemodialysis that include sustained amelioration in uremia, abnormalities in calcium/ phosphate serum levels and mineral metabolism, and anemia, all of which may adversely affect ventricular remodelling. In contrast to observed reductions in LV size and mass, there was an increase in left atrial size following AVF. This is prognostically important given the observation that an increased left atrial volume has been associated with higher mortality. 30, 31 Patients developing HF displayed more dramatic LA dilation. There was a mild decrease in LV systolic function, manifest by slight reductions in EF and LV systolic annular velocities (s'). Both EF and s' vary inversely with afterload, 32 which decreased dramatically following AVF. Therefore, these apparently minor reductions in LV systolic function are indicative of more significant reductions in LV contractile function, despite the favourable decreases in LV remodelling observed. In addition, RV dilation can negatively impact LV myocardial performance through ventricular septal interaction and paradoxical septal motion potentially leading to the observed drop in LV EF. Figure 3 Bar graphs show the prevalence of worsening right ventricular (RV) dilation and RV dysfunction after arteriovenous fistula creation among patients developing incident heart failure. 
Changes in right heart structure and function following AVF
The RV is less adept at dealing with abnormal loading conditions as compared with the LV in general, [33] [34] [35] and the haemodynamic effects of AVF/AVG importantly differ between the two ventricles. Favourable reductions in LV pressure load with dialysis are coupled to decreases in mean systemic vascular resistance owing to the low impedance AV shunt. This effectively unloads the LV. In contrast, the acute increases in venous return associated with a systemic AVF augments RV preload and chamber size, which increases RV wall stress. Since pulmonary pressure is equal to the product of flow (cardiac output) and resistance summed with downstream left heart pressures, pulmonary hypertension may develop related to high flow, further increasing RV afterload, which may culminate in RV dilation, dysfunction and clinical RV failure that is associated with increased mortality (Summary Figure) .
In contrast to reductions in LV size, there were significant increases in RV size associated with worsening RV function in the years following AVF/AVG creation in this study. These chronic longitudinal data are consistent with smaller, short-term studies. 9, 36 In this study, there was a two-to three-fold increase in the prevalence of RV dilation and dysfunction following AVF/AVG creation, presumably reflecting volume overload state induced by excess shunting, since echo-Doppler estimates of right heart pressure load did not change from Exams 1 to 2. None of the baseline structural parameters was associated with these RV changes-making it difficult to predict which patients may respond adversely to AVF/AVG creation, and lending support that AVF/AVG creation itself is responsible for RV dilation. Patients with interim coronary events and revascularization were excluded by design, eliminating a potentially important confounder to cardiac structural changes in ESRD. We show for the first time that the presence of worsening RV dilation is independently associated with increased mortality and development of HF in patients with ESRD initiating haemodialysis. These observations suggests that close monitoring may be required in patients undergoing AVF/AVG to identify any changes in right heart structure and function, which may allow for earlier intervention prior to the development of HF or death.
AVF modification
Similar to other smaller studies we were able to demonstrate beneficial effects to AVF ligation on LV size and mass. 28, [37] [38] [39] [40] 
Incidence of HF following AVF
Patients in this study displayed multiple comorbidities, with roughly half diagnosed with HF at Exam 1, in keeping with a typical ESRD population. 41 Among the remaining patients, the incidence of new onset HF was unexpectedly high at 43%, greater than previously reported. 41, 42 The greater prevalence is congruent with and may reflect the need to undergo repeat echocardiographic assessment for clinical reasons. It must be emphasized that causality cannot be either assigned or inferred between the creation of the AVF/AVG and the subsequent development of HF with this study design, but the associations between AVF with its increased flow, RV structural and functional remodelling and worse outcomes are consistent with this hypothesis. Prospective data are needed to answer these questions more definitively.
Clinical implications
Given the mortality benefit observed with AVF in large retrospective observational studies, the current data must not be interpreted to call for change in practice for access to perform renal replacement. However, these data do suggest that some patients may be more vulnerable to the deleterious haemodynamic effects of AVF/AVG, which may increase risk for development of HF and death. These risks may outweigh recognized benefits from AVF in terms of access complication rates in some patients. Intuitively, based on adverse RV remodelling and increase in atrial fibrillation and HF seen in our study, patients with borderline right heart remodelling or atrial fibrillation may be considered for alternative forms of dialysis, or at the very least close clinical and echocardiographic follow up. Strong consideration should also be given to ligation of existing fistulas in patients developing HF, right heart dysfunction, or atrial fibrillation, especially if the fistula is no longer needed, as after renal transplantation.
In this regard, our findings may be relevant to three specific considerations. First, a substantial number of patients with ESRD have HF in varying degrees, and our data suggest an increased risk for HF and death in those subsets of patients with pronounced RV dilatation or HF at baseline. Our findings thus raise the issue regarding the advisability of placement of an AVF or an AVG in those individuals with significant, pre-existing RV dysfunction or HF at the time of evaluation for vascular access placement. Indeed, a recent study examining a different patient cohort demonstrated that among patients beginning dialysis, baseline RV dysfunction was both common (present in 34%) and this was also associated with adverse outcome. 43 Second, recent studies have emphasized that the prevalence of pulmonary hypertension is substantial in patients with ESRD. 44 Although our data showed no change in estimated RA pressure or RVSP with the placement of an AVF, the RV dysfunction associated with AVF placement may be of special concern in those patients with ESRD in whom there is significant pulmonary hypertension, given the heightened afterloadsensitivity of the RV in HF. 45 Finally, while the 'Fistula First' initiative for renal replacement access broadly and appropriately guides clinical practice regarding the choice of vascular access, there is the increasing appreciation that in a limited number of specific instances, such as in patients with ESRD with limited life expectancy, a tunnelled central venous cannula may not be an unreasonable choice for dialysis vascular access. In managing such patients with substantial, life-limiting, comorbidities and high risk for right heart dysfunction, the recognition that AVFs/AVGs may be attended by HF and accompanying mortality is a germane consideration.
Limitations
The retrospective nature of the study does not address causality, and the results should be considered as hypothesis-generating rather than conclusive. A control group of ESRD patients undergoing alternative means of renal replacement (e.g. peritoneal dialysis or tunnelled CVC) without AVF was not included due to concern over confounding by indication. Future prospective trials of dialysis access Cardiac changes with AV Fistulas in ESRD assignment are essential to determine if the observed RV changes following surgical fistula creation in this study are causally related to AVF. There is indication bias in that all participants were required to have had echocardiogram performed prior to and following AVF, which may have selected for a sicker patient population. Data on AVF flow were not available. Thus we cannot determine whether high AVF flow rates contributed to the increased risk of RV dilation. Because incident HF diagnosis was determined from chart review of clinic notes, we could not accurately ascertain the time of new HF diagnosis in relationship to AVF creation. Given the burden of cardiovascular disease present at study entry and long window between cardiac examinations it is difficult to prove which factors were responsible for RV dilation. Future prospective studies with more frequent assessments would be useful to address this limitation. Medication changes between Exams 1 and 2 were not available and could have affected cardiac structure and function. The exact timing of dialysis in relationship to AVF creation was not known. However, since we studied long-term changes following fistula creation (over years), any differences of weeks to months in timing of dialysis initiation is unlikely to have strongly influenced the results. Given the retrospective nature of analysis, the timing of dialysis in relation to the echocardiogram was not ascertained. Thus we cannot exclude the possibility that RA pressures, and therefore RVSP estimates may have been affected. Although RV area and FAC was measured by the same investigator in all cases, other interpretations, including qualitative assessments of RV structure and function, were based upon interpretations performed by multiple cardiologists. However, we would expect that the increase in variability from this limitation would only bias our results toward the null, providing greater confidence in the veracity of these data. Tricuspid annular plane systolic excursion, an alternative index of RV function, was not assessed. This study design does not allow us to separate the positive effects from renal replacement and volume removal with the deleterious haemodynamic effects of the fistula. Although it is likely that these have diametrically opposite effects on the heart, future studies should seek to confirm this by comparing the long-term changes that occur with other forms of dialysis initiation and those we have observed here with AVF creation.
Conclusion
We show for the first time that over the course of years, AVF creation for the initiation of haemodialysis in patients with ESRD is associated with modest impairment in LV function despite reverse LV remodelling. There is also substantial structural and functional remodelling in the RV potentially related to increases in cardiac flow that is associated with increased risk of death and the development of HF. Given the increasing burden of ESRD worldwide and the high risk of HF in this population, further study is required to clarify the optimal use of different forms of access and renal replacement therapy to optimize outcomes for patients with or at risk for HF, and, in particular, how to identify those specific subset of patients who may be especially vulnerable to adverse RV remodelling and dysfunction.
